Centennial Wealth Advisory LLC Sells 169 Shares of AbbVie Inc. (NYSE:ABBV)

Centennial Wealth Advisory LLC lowered its position in AbbVie Inc. (NYSE:ABBV) by 7.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,029 shares of the company’s stock after selling 169 shares during the period. Centennial Wealth Advisory LLC’s holdings in AbbVie were worth $361,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. AMF Tjanstepension AB purchased a new position in AbbVie during the third quarter valued at $8,777,000. Czech National Bank lifted its position in AbbVie by 6.9% during the third quarter. Czech National Bank now owns 359,823 shares of the company’s stock valued at $71,058,000 after purchasing an additional 23,320 shares in the last quarter. City Holding Co. lifted its position in shares of AbbVie by 0.3% in the third quarter. City Holding Co. now owns 40,607 shares of the company’s stock valued at $8,019,000 after acquiring an additional 125 shares in the last quarter. Talbot Financial LLC lifted its position in shares of AbbVie by 1.5% in the third quarter. Talbot Financial LLC now owns 92,006 shares of the company’s stock valued at $18,169,000 after acquiring an additional 1,344 shares in the last quarter. Finally, Marquette Asset Management LLC purchased a new position in shares of AbbVie in the third quarter valued at about $39,000. Institutional investors own 70.23% of the company’s stock.

Insiders Place Their Bets

In other news, SVP Kevin K. Buckbee sold 1,800 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $172.24, for a total transaction of $310,032.00. Following the completion of the sale, the senior vice president now owns 6,983 shares in the company, valued at approximately $1,202,751.92. This represents a 20.49 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.25% of the stock is owned by company insiders.

AbbVie Stock Up 0.9 %

Shares of NYSE:ABBV opened at $191.74 on Thursday. AbbVie Inc. has a 52-week low of $153.58 and a 52-week high of $207.32. The stock has a market cap of $338.82 billion, a P/E ratio of 79.89, a price-to-earnings-growth ratio of 1.84 and a beta of 0.58. The business’s 50 day moving average is $177.01 and its 200 day moving average is $185.38. The company has a quick ratio of 0.54, a current ratio of 0.65 and a debt-to-equity ratio of 9.64.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, January 31st. The company reported $2.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a return on equity of 257.91% and a net margin of 7.59%. During the same period in the prior year, the firm posted $2.79 earnings per share. Sell-side analysts predict that AbbVie Inc. will post 12.26 EPS for the current year.

Analyst Upgrades and Downgrades

ABBV has been the topic of several research analyst reports. Citigroup boosted their price objective on AbbVie from $205.00 to $215.00 and gave the company a “buy” rating in a research report on Monday. Daiwa Capital Markets downgraded AbbVie from an “outperform” rating to a “neutral” rating and set a $180.00 price objective on the stock. in a research report on Thursday, December 5th. Guggenheim boosted their target price on AbbVie from $212.00 to $214.00 and gave the stock a “buy” rating in a research report on Monday. Bank of America reiterated a “neutral” rating and issued a $191.00 target price on shares of AbbVie in a research report on Tuesday, December 10th. Finally, UBS Group boosted their target price on AbbVie from $181.00 to $190.00 and gave the stock a “neutral” rating in a research report on Monday. Five investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $208.35.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.